ArticleMolecular biology reports2026
Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CXCL12/CXCR4 signaling axis drives ovarian cancer progression, metastasis, and chemoresistance, making it a key therapeutic target. However, the biological consequences of prolonged high-dose inhibition remain poorly characterized. This study investigated the dose-dependent molecular and functional effects of prolonged exposure to the selective CXCR4 antagonist USL311 in heterogeneous ovarian cancer models (ES2 and HAY cell lines).
methodsCells were treated with 50, 75, or 100 µM USL311 for 72 h. Western blot, immunofluorescence, cytotoxicity, and wound-healing assays evaluated signaling cascades, protein expressions, and functional outcomes.
resultsCXCR4 inhibition triggered highly discrete, lineage-specific molecular responses. ES2 cells exhibited a prominent biphasic pattern; 50 µM USL311 significantly suppressed CXCR4 and Cyclin D1 expression, but higher concentrations induced a paradoxical rebound expression driven by a HIF1α-dependent adaptive stress mechanism, despite p-AKT suppression and marked cytotoxicity. Conversely, HAY cells bypassed this cascade via a HIF1α-independent pathway, initiating a compensatory escape network marked by a structural rebound in p-AKT activation and significant upregulation of metastatic enzymes MMP2 and MMP9 under identical conditions.
conclusionCXCR4 inhibition induces highly complex, concentration- and cell-line-dependent biological responses. Moderate inhibition effectively suppressed oncogenic signaling pathways, whereas excessive inhibition triggered paradoxical compensatory responses that vary across ovarian cancer subtypes. These findings highlight the critical importance of therapeutic dose optimization and provide crucial mechanistic insights into the limitations of high-dose CXCR4-targeted therapy in ovarian cancer.
Indexed as
Identifiers
42886399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.